JP5926616B2 - Aging inhibitor - Google Patents

Description

  The present invention relates to suppression of aging.

  In animals including humans, the function of an individual decreases with age, for example, a decrease in visual acuity or hearing, a decrease in motor ability, a decrease in immune function, memory impairment, and a decrease in function of each organ in a living body. Such a decrease in function of the individual is called aging. Aging is a multifaceted phenomenon that gradually progresses in various tissues and organs of an individual. As aging progresses, the individual can no longer maintain its homeostasis and eventually die.

  Currently, in developed countries, people's life expectancy has been significantly extended due to the development of medical technology, but on the other hand, elderly people suffer from various problems such as impaired life due to deterioration of mental and physical functions accompanying aging. Have problems such as suffering from various diseases. Increasing welfare and medical costs for the elderly are a serious problem in developed countries. Therefore, if the individual's homeostasis can be maintained and the lifespan can be extended without causing deterioration of mental and physical functions and diseases associated with aging, it is useful from the viewpoint of welfare and medical expenses control and individual quality of life (QOL). It is.

  Several compounds have been reported so far as agents that have the effect of inhibiting aging or extending lifespan. For example, it has been reported that resveratrol, which is a kind of polyphenol contained in wine, can extend the life of mice that have ingested a high-calorie diet (Non-patent Document 1). However, development of a more effective aging inhibitor is desired.

  A sirtuin gene is a gene that has been reported to contribute to the extension of the lifespan of an organism through its activation. Sirtuin genes are also called longevity genes or anti-aging genes. Sirtuin genes such as yeast Sir2 and mammalian SIRT1-7 are known, and encode a protein sirtuin. Sirtuins act as NAD-dependent histone deacetylases and remove acetyl groups of acetylated proteins on transcription factors such as histones and p53. When a sirtuin gene is activated, sirtuin expression increases, and as a result, the expression of various genes is regulated, and it is considered that the life span is extended (Non-patent Document 2). The life extension effect by sirtuin gene activation has been reported in yeast (Non-patent Documents 3 and 4), nematodes (Non-patent Document 5), Drosophila (Non-patent Document 6), and mice (Non-patent Document 7). .

  It is believed that the sirtuin prolongation effect is due to various effects brought about by increased sirtuin expression or activation of sirtuin proteins. Such actions include an action that suppresses physiological functional decline due to aging (Non-patent Document 8), an action that recovers damage caused by autoimmunity (Non-Patent Document 9), and a cell that is caused by a malfunction of the telomere gene. Actions to restore proliferative defects, actions to recover from disorders caused by neurodegeneration (eg Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis), recovery of neurotrophic factor gene decline in the brain In addition, an effect of improving learning and memory ability (Non-Patent Document 10) can be considered.

  As factors that activate sirtuins or suppress aging, caloric restriction and resveratrol have been known (Non-Patent Documents 2, 4, etc.). More recently, as a compound having a sirtuin activating action stronger than that of resveratrol, an extract of a fruit or seed of a gnetum plant, or gnetin C (Patent Document 1), and ε-viniferin (Patent Document 2) are disclosed. It was.

  Alkyl resorcinol is a compound contained in many plants and fungi such as wheat and rye. Alkyl resorcinol is known as an inhibitor of intestinal carbohydrate hydrolase (Patent Document 3) and has been suggested to be involved in the nutritional inhibitory effect of rye (Non-Patent Document 11). However, it has not been known so far that alkylresinol directly activates sirtuin proteins and contributes to aging inhibition.

JP 2011-079797 A JP 2011-057580 A JP-A-5-170645

Baur et al, Nature, 444: 337-342 (2006) Tissenbaum and Guarente, Dev Cell, 2: 9-19 (2002) Kaeberlein et al, Genes Dev, 13: 2570-2580 (1999) Howitz et al, Nature 425: 191-196 (2003) Tissenbaum and Guarente, Nature, 410: 227-230 (2001) Rogina and Helfand, Proc Natl Acad Sci U S A, 101: 15998-16003 (2004) Kanfi et al, Nature 483: 218-221 (2012) Colak Y et al, Med Sci Monit. May; 17 (5): HY5-9 (2011) Kong S et al, Immunol Cell Biol. Jan; 90 (1): 6-13 (2012) Carafa V et al, Front Pharmacol. 3: 4. Epub (2012) Ross et al, Nutrition Review, 62: 81-95 (2004)

  It is an object of the present invention to provide a material that is effective in maintaining the homeostasis of a living body, can prevent the aging of an individual, extend the life span, and is safe even if ingested continuously for a long period of time.

  As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that alkylresorcinols having a specific structure have a sirtuin activating action and an aging-inhibiting action, and an effect of extending the life of an individual. The present invention has been completed.

That is, the present invention provides the following formula (I):
(Wherein R ₁ represents a saturated or unsaturated linear or branched alkyl group, and R ₂ represents a hydrogen atom or a methyl group)
The sirtuin activator which uses the compound represented by these as an active ingredient is provided.
Moreover, this invention provides the aging inhibitor which uses the compound represented by the said formula (I) as an active ingredient.

  According to the sirtuin activator and the aging inhibitor of the present invention, the lifespan can be extended while maintaining the functions and homeostasis of the living body. Moreover, according to the agent of the present invention, aging of an individual can be suppressed and its life can be extended. Furthermore, since alkylresorcinol, which is an active ingredient of the agent of the present invention, is an ingredient contained in cereals, there are no harmful side effects even when taken continuously, and safety is high.

Sirtuin activation by a compound of formula (I). Sirtuin activation by a compound of formula (I). The survival curve of male Drosophila measured in Test Example 3. The female Drosophila survival curve measured in Test Example 3. The average life span of male Drosophila as measured in Test Example 3. Error bar = standard deviation Life expectancy of female Drosophila measured in Test Example 3. Error bar = standard deviation

  The sirtuin activator or aging inhibitor of the present invention comprises an alkylresorcinol compound represented by the following formula (I) (hereinafter, also referred to as formula (I) compound) as an active ingredient.

In formula (I), R ₁ represents a saturated or unsaturated linear or branched alkyl group. The number of carbon atoms of the alkyl group represented by R ₁ is not limited, but is preferably 1 to 23, more preferably 3 to 23, still more preferably 5 to 21, still more preferably 5, 7, 9, 11, 13, 15, 17, 19 and 21.

Preferably, R ₁ is a saturated or unsaturated linear alkyl group, more preferably a saturated linear alkyl group. Examples of the saturated linear alkyl group represented by R ₁ include methyl, n-propyl, n-pentyl, n-heptyl, n-nonyl, n-undecyl, n-tridecyl, n-pentadecyl, n-heptadecyl, Examples include n-nonadecyl, n-henicosyl, n-tricosyl and the like.
The position and number of unsaturated bonds of the unsaturated linear alkyl group represented by R ₁ are not particularly limited. Examples of the unsaturated linear alkyl group include an alkyl group having an unsaturated bond at an arbitrary position on the carbon chain of the above-described saturated linear alkyl group.
The position and number of branches of the saturated or unsaturated branched alkyl group represented by R ₁ and the position and number of unsaturated bonds are not particularly limited.

In formula (I), R ₂ represents a hydrogen atom or a methyl group, preferably a hydrogen atom.

In formula (I), R ₁ is preferably located in the para position of R ₂ .

Preferred examples of the compound of formula (I) include the following.
5-pentylresorcinol [olibutol or 1,3-dihydroxy-5-n-pentylbenzene (C5: 0)]
5-heptylresorcinol [or 1,3-dihydroxy-5-n-heptylbenzene (C7: 0)]
5-nonylresorcinol [or 1,3-dihydroxy-5-n-nonylbenzene (C9: 0)]
5-undecylresorcinol [or 1,3-dihydroxy-5-n-undecylbenzene (C11: 0)]
5-tridecylresorcinol [or 1,3-dihydroxy-5-n-tridecylbenzene (C13: 0)]
5-pentadecylresorcinol [or 1,3-dihydroxy-5-n-pentadecylbenzene (C15: 0)]
5-heptadecylresorcinol [or 1,3-dihydroxy-5-n-heptadecylbenzene (C17: 0)]
5-nonadecylresorcinol [or 1,3-dihydroxy-5-n-nonadecylbenzene (C19: 0)]
5-Henicosyl resorcinol [or 1,3-dihydroxy-5-n-henicosylbenzene (C21: 0)]
5-tricosylresorcinol [or 1,3-dihydroxy-5-n-tricosylbenzene (C23: 0)]

  The said formula (I) compound can obtain a commercial item, and can be extracted from a plant by a conventional method. Commercially available products can be purchased from ResearchChem GmbH, SIGMA-ALDRICH, and the like. Furthermore, the compound of the said formula (I) can also be manufactured by a chemical synthesis method with reference to international publication WO2007 / 77770 pamphlet etc.

  Plants containing the compound of formula (I) include urushiaceae, ginkgoaceae, caterpillaraceae, scorpionaceae, primrose, asteraceae, iris family, taro family, legume family, gramineous family, Artemisia is mentioned. Among these plants, gramineous plants are preferable as a raw material for the compound of formula (I) because they contain alkylresorcinol in the edible part. Among grasses, wheat and rye are more preferable. Furthermore, wheat and rye moss and whole grains contain abundantly the compound of formula (I) (about 0.015 to 0.3% by mass of the total grain mass), so that of the compound of formula (I) A more preferable example of the raw material is mentioned. A fermented product of the grass family is also mentioned as a preferred example of the raw material of the compound of formula (I).

  As a method for extracting the compound of formula (I) from the above-mentioned plant, a method of immersing the above-mentioned plant or a fermented product thereof in an extraction solvent heated at room temperature or under normal pressure or with stirring as necessary, reflux extraction Law, etc. The plant may be subjected to cutting, crushing, pressing, drying, or combinations thereof as needed before being added to the extraction solvent.

  Examples of the extraction solvent include alcohols that are liquid at room temperature, such as lower alcohols such as methanol, ethanol, n-propanol, isopropanol, and n-butanol, and polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, and glycerin. Ethers such as diethyl ether and propyl ether; esters such as butyl acetate and ethyl acetate; ketones such as acetone and ethyl methyl ketone; hexane; and organic solvents such as chloroform. These solvents may be used alone or in combination of two or more. Of the above solvents, alcohols that are liquid at room temperature, for example, lower alcohols having 1 to 4 carbon atoms, are preferably used from the viewpoint of operability and environmental impact, and from the viewpoint of safety due to residual solvents. More preferably, ethanol is used.

  The organic solvent may further include a water-containing organic solvent containing an aqueous component. From the viewpoint of maintaining high extraction efficiency, the content of the aqueous component in the water-containing organic solvent is usually 50% by volume or less, preferably 30% by volume or less, more preferably 20% by volume or less. Examples of the water-containing organic solvent include a water-containing alcohol in which an aqueous component is further contained in the alcohol that is liquid at room temperature as described above, and more preferably water-containing ethanol.

  The temperature and time for extraction can be appropriately set depending on the type of extraction solvent used and the extraction conditions, but the extraction temperature is preferably 2 to 100 ° C. and the extraction time is preferably about 30 minutes to 60 hours. . The amount of the extraction solvent is preferably about 200 to 2000 parts by mass with respect to 100 parts by mass of the Gramineae plant or its fermented product.

  Next, the mixture containing the extract and the residue is subjected to filtration or centrifugation as necessary, and the solid component that is the residue is removed to obtain an extract containing the compound of formula (I). It should be noted that the removed solid component can be subjected again to an extraction operation using an extraction solvent, and this operation may be repeated several times. The obtained extract is preferably further purified by liquid chromatography or the like. The extract containing the compound of formula (I) thus obtained is subjected to further treatment such as concentration, freeze-drying, hot-air drying, pulverization, pulverization, classification, dilution, and water mixing as it is or as necessary. Once applied, it can be used in the present invention.

  The compound of formula (I) has an action of activating the sirtuin protein SIRT1 and an action of extending the life of an individual animal, as shown in the Examples described later. Therefore, the compound of formula (I) can be used for sirtuin activation, prolongation of life span, suppression of aging, prevention or improvement of diseases and conditions that may occur with aging, and the like.

  Accordingly, the present invention provides a sirtuin activator comprising a compound of formula (I) as an active ingredient. The present invention also provides an aging inhibitor comprising a compound of formula (I) as an active ingredient. The present invention also provides a life extending agent comprising a compound of formula (I) as an active ingredient. The present invention also provides a preventive or ameliorating agent for a disease or condition that can occur with aging, comprising a compound of formula (I) as an active ingredient. In one embodiment, the agent may consist essentially of a compound of formula (I). In another embodiment, the agent comprises a plant extract containing a compound of formula (I), preferably a wheat or rye extract.

In the present specification, “aging” refers to a decrease in the physiological function of an animal individual that occurs with aging, for example, a decrease in visual acuity or hearing, a decrease in motor ability, a decrease in homeostatic function, a decrease in immune function, memory impairment, etc. Decrease in brain function, and decrease in function of each organ in the living body. In the present specification, “aging suppression” refers to suppression of decrease in physiological function of an animal individual that occurs with the above-mentioned aging, suppression of diseases and disorders caused by the decrease in physiological function, and suppression of death of an individual due to progress of aging ( That is, it is a concept that includes the extension of life.
In addition, in the present specification, the “disease or condition that can occur with aging” refers to various diseases and conditions that are caused by the above-described decrease in physiological function of the animal individual that occurs with aging, for example, disorders due to autoimmunity, telomere gene defects Cell proliferation defects caused by neuropathy, disorders caused by neurodegeneration (eg Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis), impaired neurotrophic factor gene function in the brain, learning, memory ability A drop etc. are mentioned.

  Since the compound of formula (I) is a component contained in wheat and rye with abundant dietary experience, it is a safe compound with little fear of causing harmful effects on the living body even if taken continuously for a long period of time. . Therefore, the compound of the formula (I) can be safely and continuously inoculated not only for healthy persons and adults but also for elderly persons or sick persons who particularly need the present invention. Accordingly, the compound of formula (I) is useful as a human or animal medicine, food and drink, feed, or the like, or for producing them.

  Therefore, this invention also provides the pharmaceutical, food-drinks, and feed which contain a compound of Formula (I) as an active ingredient. The said medicine, food-drinks, and feed can be used for sirtuin activation, life extension, aging inhibition, prevention or improvement of diseases and conditions that may occur with aging, and the like.

  The medicament may be a sirtuin activator containing a compound of formula (I) as an active ingredient, a life extension agent, an aging inhibitor, a preventive or ameliorating agent for diseases and conditions that may occur with aging, and the like. Examples of the pharmaceutical dosage form include oral preparations such as tablets, capsules, granules, powders, syrups, dry syrups, liquids and suspensions, and enteral preparations such as inhalants, transdermal preparations, and suppositories. Examples include parenteral preparations such as preparations, instillations, and injections. Liquid preparations such as the above-mentioned liquids and suspensions may be in the form of being dissolved or suspended in water or other suitable medium immediately before taking, and the tablets and granules are coated on the surface by a well-known method. It may be. The injection may be a solution of the compound of formula (I) in sterile distilled water or sterile physiological saline containing a solubilizing agent as necessary.

  In addition to the compound of formula (I) which is an active ingredient, the medicament contains various pharmaceutically acceptable carriers, for example, excipients, stabilizers, other additives and the like as necessary. Alternatively, it may further contain other medicinal ingredients such as various vitamins, minerals, herbal medicines and the like. The said pharmaceutical can be manufactured in accordance with a conventional method by mix | blending the above-mentioned carrier and other medicinal ingredients with the formula (I) compound or a plant extract containing it.

  The above-mentioned food or drink or feed contains the compound of formula (I) as an active ingredient, and intends effects such as sirtuin activation, life extension, aging inhibition, prevention or improvement of diseases and conditions that may occur with aging, etc. In addition, health food, functional food and drink, food and drink for specified health use, food and drink for the sick, livestock, racehorse, feed for appreciation animals, pet food, etc.

  The form of the said food-drinks and feed is not restrict | limited in particular, All the forms which can mix | blend a formula (I) compound are contained. For example, the form may be solid, semi-solid or liquid, or various forms such as tablets, chewable tablets, powders, capsules, granules, drinks, gels, syrups, liquid foods for enteral nutrition. .

Specific examples of the form of food and drink include tea drinks such as green tea, oolong tea and tea, coffee drinks, soft drinks, jelly drinks, sports drinks, milk drinks, carbonated drinks, fruit juice drinks, lactic acid bacteria drinks, fermented milk drinks, Powdered beverages, cocoa beverages, alcoholic beverages, beverages such as purified water, butter, jam, sprinkles, margarine spreads, mayonnaise, shortening, cream, dressings, breads, cooked rice, noodles, pasta, miso soup, tofu, Examples include milk, yogurt, soup or sauce, confectionery (for example, biscuits and cookies, chocolate, candy, cake, ice cream, chewing gum, and tablet).
Since the said feed can be utilized by the composition and form substantially the same as the said food / beverage products, the description regarding the food / beverage products in this specification can be applied similarly to feed.

  The above food and drink and the formula (I) compound or a plant extract containing the compound, other food and drink materials used in the production of food and drink and feed, various nutrients, various vitamins, minerals, amino acids, various fats and oils, various And other additives (for example, flavoring ingredients, sweeteners, acidulants such as organic acids, surfactants, pH adjusters, stabilizers, antioxidants, pigments, flavors), etc. Can do. Or the food / beverage products or feed concerning this invention can be manufactured by mix | blending a formula (I) compound or the plant extract containing it with the food / beverage products or feed currently eaten normally.

  The content of the compound of formula (I) in the above-mentioned medicine, food or drink or feed may be an amount that can provide the desired sirtuin activation effect, life extension effect, aging inhibitory effect, etc. The form may be appropriately changed depending on the type, symptom, age, sex, etc. of the individual to be administered or ingested. When targeting humans, the preferred dosage of the compound of formula (I) is usually 0.01 to 10 g per day per adult. The daily dose may be administered once, but may be divided into several times. The pharmaceutical dosage form or administration regimen, or the form of the food or drink or feed is preferably in a form that allows the dosage to be appropriately managed.

  The present invention will be specifically described by the following examples, but the present invention is not limited to these examples.

Production Example 1 Production of rye extract containing compound of formula (I) 2 g of rye husk was pulverized with a multi-bead shocker (multi-sample cell crusher / MB301 (S): manufactured by Yasui Kikai Co., Ltd.). Of ethanol, and extracted by shaking for 2 hours at 150 rpm and room temperature, then centrifuged for 15 minutes at 3500 rpm and room temperature, and the supernatant was dried with a centrifugal concentrator to obtain an extract of rye hull ethanol. Got. When this extract was purified and analyzed using high performance liquid chromatography, 1,3-dihydroxy-5-n-pentadecylbenzene (C15: 0), 1,3-dihydroxy-5-n-heptadecylbenzene was analyzed. (C17: 0), 1,3-dihydroxy-5-n-nonadecylbenzene (C19: 0), and 1,3-dihydroxy-5-n-henicosylbenzene (C21: 0) in a total of about 80 % Content.

Test Example 1 Sirtuin Activation-1 by Compound (I)
As a test compound, 1,3-dihydroxy-5-n-heptadecylbenzene (C17: 0) (purchased from ResearchChem GmbH) was used. The activation of sirtuin SIRT1 was measured by the method shown below using SIRT1 / Sir2 Decelacease Fluorometric Assay Kit (Cyclex). A solution of the test compound adjusted to each concentration with ethanol was added to a final concentration of 50 mM Tris-HCl (pH 8.8), 0.5 mM DTT, 0.25 mAU / ml lysylepteptidase, 1 μM Trichostatin A, 200 μM NAD, 20 μM fluorescent substrate peptide and 0.02 U / mL SIRT1 enzyme were added and mixed. As a control, ethanol alone was added instead of the test compound solution. The fluorescence of the mixture was measured at 25 ° C. for 60 minutes using a fluorescent plate reader at an excitation wavelength of 350 nm and an emission wavelength of 450 nm.

  The kinetics curve of SIRT1 activation by the test compound (final concentration 10 μM) is shown in FIG. Compared to the control, the initial rate of change in fluorescence intensity by the test compound was increased, confirming that the test compound directly activated the SIRT1 enzyme activity.

Test Example 2 Sirtuin Activation-2 by Formula (I) Compound
As a test compound, olivetol [1,3-dihydroxy-5-n-pentylbenzene (C5: 0)] (purchased from SIGMA-ALDRICH) was used, and fluorescence kinetics was measured in the same procedure as in Test Example 1. And SIRT1 enzyme activity was evaluated. Final concentrations of test compounds were 1, 10 and 100 μM. The increase rate of the fluorescence intensity with respect to the control (ethanol) at a reaction time of 1000 seconds is shown in FIG. It was shown that SIRT1 enzyme activity was enhanced in a concentration-dependent manner by the test compound.

Test Example 3 Extending Drosophila Survival by Formula (I) Compound (Preparation of Drosophila)
As a test subject, Drosophila melanogaster W1118, which is a strain treated as a wild type equivalent in many Drosophila studies and described in Magwire et al, PLoS Genet, 6: e1001037, 2010, etc., was used in the Drosophila Genetic Resource Center ( Used in Kyoto City Ukyo-ku, Kyoichi Hongi-cho, Kyoto Institute of Technology). For passage of Drosophila, normal media (10% D-glucose, 7% corn meal, 4% ebios, 0.55% agar, and 0.3% propionic acid, 0.35% p-butyl as preservatives) are used. p-hydroxybenzoate was used).
Drosophila adults were released into a breeding container (vial bottle: diameter 3 cm × height 9 cm) on which the medium was spread, and reared in a room kept at room temperature 25 ° C., 12 hours light and dark, and humidity 50%. Adults lay eggs on the medium, and hatched larvae crawl on the side of the vial and become pupae. Adults emerged from the pupae were transferred to a new breeding container and subcultured. The medium was changed every 4 to 5 days.
(Test medium)
0.07% by mass of the purified rye shell ethanol extract prepared in Production Example 1 in the above normal medium as a compound of formula (I) (mixture of C15: 0, C17: 0, C19: 0, C21: 0) The medium added to become the test medium. As a positive control, a normal medium prepared by adding 100 μM resveratrol to the normal medium was used, and a normal medium without compound was used as a negative control.
(Lifetime measurement)
The procedure for measuring the Drosophila survival time in this test example is described in a general method for measuring the survival time of adult Drosophila individuals (for example, Muffat et al, Proc Natl Acad Sci USA, 105: 7088-7093, 2008). Method). 20 males or 20 females were bred in each vial and placed in a vial with each medium, and adult Drosophila immediately after emergence. 24 vials of male and female were prepared. The flies were transferred to fresh medium twice a week and the number of dead flies was counted at the time of medium change. For each of males and females, the average value of the survival days of all individuals was determined and used as the average life span.

  FIG. 3 shows the survival curve of male Drosophila, and FIG. 4 shows the survival curve of female Drosophila. In both male and female Drosophila, the survival time was prolonged in the test medium group containing the compound of formula (I) as compared to the negative control. The survival time of the test medium group was extended to the same level or higher in males as in the positive control (resveratrol) group, while in females, the survival period in the positive control group was not significant, but positive It was significantly extended compared to the control group. The average life spans of male and female Drosophila are shown in FIGS. 5 and 6, respectively. The average life span of the test medium group was extended by about 10 days compared to the negative control. In males, both the test medium group and the positive control group significantly extended the average life span (P ≦ 0.005). In females, the test media group significantly (P ≦ 0.005) extended the average lifespan compared to the negative control group.

Claims (7)

Formula (I)
(Wherein, R ₁ represents a saturated KazuTadashikusaria alkyl group of 1 to 23 carbon atoms, R ₂ is tables hydrogen atom, R ₁ is located in the para position of the R ₂₎
A sirtuin activator comprising as an active ingredient the compound represented by (except when used as an NFκB inhibitor for the suppression of skin aging) . The compound represented by the formula (I) is 5-pentyl resorcinol, 5-heptyl resorcinol, 5-nonyl resorcinol, 5-undecyl resorcinol, 5-tridecyl resorcinol, 5-pentadecyl resorcinol, 5-heptadecyl resorcinol, The sirtuin activator according to claim 1, selected from 5-nonadecyl resorcinol, 5-henicosyl resorcinol, and 5-tricosyl resorcinol. The sirtuin activator according to claim 1 or 2 , comprising a wheat or rye extract containing the compound represented by the formula (I). Formula (I)
(Wherein, R ₁ represents a saturated KazuTadashikusaria alkyl group of 1 to 23 carbon atoms, R ₂ is tables hydrogen atom, R ₁ is located in the para position of the R ₂₎
An anti-aging agent comprising the compound represented by (except when used as an NFκB inhibitor for inhibiting skin aging) . The compound represented by the formula (I) is 5-pentyl resorcinol, 5-heptyl resorcinol, 5-nonyl resorcinol, 5-undecyl resorcinol, 5-tridecyl resorcinol, 5-pentadecyl resorcinol, 5-heptadecyl resorcinol, The aging inhibitor according to claim 4, which is selected from 5-nonadecyl resorcinol, 5-henicosyl resorcinol, and 5-tricosyl resorcinol. The aging inhibitor according to claim 4 or 5 , comprising a wheat or rye extract containing the compound represented by the formula (I). The aging inhibitor according to any one of claims 4 to 6 , which is used for extending the life.